TABLE 6.
Overview of the majora studies investigating the effects of statin treatment on changes of lathosterol and campesterol
| Author | Year | Statin | N | Duration | Total cholesterol Changes, % | Lathosterol Changes, % | Lathosterol/C Changes, % | Campesterol Change, % | Campesterol/C Change, % |
|---|---|---|---|---|---|---|---|---|---|
| Uusitupa et al. (37) | 1992 | Lovastatin (80 mg/day) | 62 | 18 weeks | −34% | −63% | −43% | −14% | +33% |
| Miettinen et al. (11) | 2000 | Simvastatin (20 mg/day) | 434 | 6 weeks | NR | NR | −34% | NR | NR |
| Miettinen et al. (38) | 2002 | Simvastatin (20m//day) | 319 | 1 year | −30% | −55% | −36% | +4% | +48% |
| Simvastatin (40 mg/day) | 115 | 1 year | −27% | −52% | −35% | +4% | +46% | ||
| Miettinen et al. (21) | 2003 | Atorvastatin (29 mg/dayb) | 102 | 1 year | −36% | NR | −52% | NR | +74% |
| Simvastatin (34 mg/dayb) | 105 | 1 year | −33% | NR | −43% | NR | +33% | ||
| Assmann, et al. (39) | 2008 | Atorvastatin (10–80 mg/day) | 160 | 12 weeks | −33% | −69% | −59% | +10% | +58% |
| Simvastatin (10–80 mg/day) | 232 | 12 weeks | −27% | −54% | −42% | −2% | +35% | ||
| Van Himbergen et al. | Current study | Rosuvastatin (40 mg/day) | 66 | 6 weeks | −40% | −78% | −64% | −2% | +52% |
| Atorvastatin (80 mg/day) | 69 | 6 weeks | −40% | −81% | −68% | +5% | +72% |
NR, not reported.
a
Inclusion criteria: statin studies with more than 50 participants, including lathosterol and campesterol measurements as markers for synthesis and absorption, respectively.
b
Average dose over a 1-year treatment period.